Patents by Inventor Kazuyasu Nakamura
Kazuyasu Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050272918Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor ? chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor ? chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.Type: ApplicationFiled: August 1, 2005Publication date: December 8, 2005Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Masamichi Koike, Akiko Furuya, Kazuyasu Nakamura, Akihiro Iida, Hideharu Anazawa, Nobuo Hanai, Kiyoshi Takatsu
-
Publication number: 20050262593Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-modulated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: May 18, 2005Publication date: November 24, 2005Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 6946292Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: October 9, 2001Date of Patent: September 20, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20050187380Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: ApplicationFiled: March 31, 2005Publication date: August 25, 2005Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Patent number: 6872392Abstract: Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.Type: GrantFiled: July 16, 2002Date of Patent: March 29, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Publication number: 20050031613Abstract: A medicament for treating Fc?RIIIa polymorphism patients who cannot be treated by a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain.Type: ApplicationFiled: April 9, 2003Publication date: February 10, 2005Inventors: Kazuyasu Nakamura, Kenya Shitara, Shigeki Hatanaka, Rinpei Niwa, Akira Okazaki
-
Publication number: 20040259150Abstract: A method for enhancing a binding activity of an antibody composition to Fc&ggr; receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fc&ggr; receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through &agr;-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.Type: ApplicationFiled: April 9, 2003Publication date: December 23, 2004Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kazuyasu Nakamura, Kenya Shitara
-
Publication number: 20040253234Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.Type: ApplicationFiled: May 19, 2004Publication date: December 16, 2004Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
-
Publication number: 20040136996Abstract: The present invention provides an apoptosis inducer and a therapeutic agent for eosinophilic diseases which comprises, as an active ingredient, an antibody which reacts specifically with eosinophils and induces apoptosis of eosinophils; and a method for inducing eosinophil apoptosis using the antibody, and a method for specifically reducing or removing eosinophils in peripheral blood or tissues using the antibody.Type: ApplicationFiled: December 23, 2002Publication date: July 15, 2004Inventors: Emi Hosaka, Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai
-
Publication number: 20040091480Abstract: A method for preventing or treating a disease, comprising administering to human or animal in need of such prevention or treatment an effective amount of a monoclonal antibody which specifically binds to FGF-8 and inhibits FGF-8 activity.Type: ApplicationFiled: May 9, 2003Publication date: May 13, 2004Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Nobuo Hanai, Motoo Yamasaki, Akiko Furuya, Akira Tanaka, Kenya Shitara, Naoki Shimada, Kazuyasu Nakamura, Maiko Hirota
-
Publication number: 20030175273Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: August 30, 2002Publication date: September 18, 2003Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Tanaka, Masamichi Koike
-
Publication number: 20030115614Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: October 9, 2001Publication date: June 19, 2003Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20030096977Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor &agr; chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor &agr; chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.Type: ApplicationFiled: October 29, 2002Publication date: May 22, 2003Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Masamichi Koike, Akiko Furuya, Kazuyasu Nakamura, Akihiro Iida, Hideharu Anazawa, Nobuo Hanai, Kiyoshi Takatsu
-
Publication number: 20030088075Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.Type: ApplicationFiled: June 4, 2002Publication date: May 8, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi Shibuya
-
Publication number: 20030077276Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2.Type: ApplicationFiled: July 16, 2002Publication date: April 24, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 6538111Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor &agr; chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor &agr; chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.Type: GrantFiled: November 5, 1999Date of Patent: March 25, 2003Assignee: Kyowa Hakko Kogyo Co., LTDInventors: Masamichi Koike, Akiko Furuya, Kazuyasu Nakamura, Akihiro Iida, Hideharu Anazawa, Nobuo Hanai, Kiyoshi Takatsu
-
Publication number: 20020098527Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: ApplicationFiled: March 2, 2001Publication date: July 25, 2002Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Patent number: 6423511Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2.Type: GrantFiled: September 10, 1999Date of Patent: July 23, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 6042828Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.Type: GrantFiled: June 27, 1996Date of Patent: March 28, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 6018032Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor .alpha. chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor .alpha. chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.Type: GrantFiled: May 9, 1997Date of Patent: January 25, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Masamichi Koike, Akiko Furuya, Kazuyasu Nakamura, Akihiro Iida, Hideharu Anazawa, Nobuo Hanai, Kiyoshi Takatsu